Arca
Skip to content
Tools
Tools

PPARG: Peroxisome proliferator-activated receptor gamma

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Ligand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-oxidation of fatty acids.

  • Drugs that act on it: 30
  • Approved: 6
  • In phases 1 to 3: 24
  • Sponsors: 19

Who Is On It, and How Far Along

Every drug ChEMBL records acting on PPARG, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Other

Approved6

  • Pioglitazone
  • Mesalamine
  • Rosiglitazone
  • Balsalazide
  • Olsalazine
  • Troglitazone

Phase 310

  • Saroglitazar
  • Leriglitazone
  • Aleglitazar
  • Balaglitazone
  • Bardoxolone methyl
  • Imiglitazar
  • MK-0767
  • Muraglitazar
  • Rivoglitazone
  • Tesaglitazar

Phase 212

  • Arhalofenate
  • ATX08-001
  • DB959
  • Efatutazone
  • Etalocib
  • Farglitazar
  • INT131
  • MBX-2044
  • MK-0533
  • Naveglitazar
  • Netoglitazone
  • OMS405

Phase 12

  • AVE0847
  • CLX-0921

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

Modalities

Drugs on this target by ChEMBL molecule type.

  • Small molecule2790%
  • Other310%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 22 of 30 act as: Peroxisome proliferator-activated receptor gamma agonist; the rest name their own mechanism.
PioglitazoneApprovedTakeda Pharmaceuticals USASmall moleculeAgonist—52Boxed warning
MesalamineApprovedViatrisSmall moleculeAgonist—28—
RosiglitazoneApprovedWoodwardSmall moleculeAgonist—3WithdrawnBoxed warning
BalsalazideApprovedBausch HealthSmall moleculeAgonist—0—
OlsalazineApprovedViatrisSmall moleculeAgonist—0—
TroglitazoneApprovedSankyoSmall moleculeAgonist—0Withdrawn
SaroglitazarPhase 3Zydus Therapeutics Inc.Small moleculeAgonist—5—
LeriglitazonePhase 3Minoryx Therapeutics, S.L.Small moleculeAgonist—1—
AleglitazarPhase 3RocheSmall moleculeAgonist—0—
BalaglitazonePhase 3—Small moleculePartial agonistPeroxisome proliferator-activated receptor gamma partial agonist0—
Bardoxolone methylPhase 3BiogenSmall moleculeAntagonistPeroxisome proliferator-activated receptor gamma antagonist0—
ImiglitazarPhase 3Takeda Pharmaceuticals USASmall moleculeAgonist—0—
MK-0767Phase 3Merck & Co. (MSD)Small moleculeAgonist—0—
MuraglitazarPhase 3Bristol-Myers SquibbSmall moleculeAgonist—0—
RivoglitazonePhase 3Daiichi SankyoSmall moleculeAgonist—0—
TesaglitazarPhase 3AstraZeneca PharmaceuticalsSmall moleculeAgonist—0—
ArhalofenatePhase 2Gilead SciencesSmall moleculeModulatorPeroxisome proliferator-activated receptor gamma modulator0—
ATX08-001Phase 2Astellas PharmaSmall moleculeModulatorPeroxisome proliferator-activated receptor gamma modulator0—
DB959Phase 2T3D Therapeutics, Inc.OtherAgonist—0—
EfatutazonePhase 2Daiichi SankyoSmall moleculeAgonist—0—
EtalocibPhase 2Eli LillySmall moleculeAgonist—0—
FarglitazarPhase 2GSKSmall moleculeAgonist—0—
INT131Phase 2InteKrin Therapeutics, Inc.Small moleculeModulatorPeroxisome proliferator-activated receptor gamma modulator0—
MBX-2044Phase 2Gilead SciencesOtherModulatorPeroxisome proliferator-activated receptor gamma modulator0—
MK-0533Phase 2Merck & Co. (MSD)Small moleculeModulatorPeroxisome proliferator-activated receptor gamma modulator0—
NaveglitazarPhase 2Eli LillySmall moleculeAgonist—0—
NetoglitazonePhase 2—Small moleculeModulatorPeroxisome proliferator-activated receptor gamma modulator0—
OMS405Phase 2—Small moleculeAgonist—0—
AVE0847Phase 1—OtherAgonist—0—
CLX-0921Phase 1—Small moleculeAgonist—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov.
A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney DiseasePioglitazone, RosiglitazonePhase 2Active, not recruitingBeijing University of Chinese Medicine2026-10-30
Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisPioglitazonePhase 4RecruitingMadrigal Pharmaceuticals, Inc.2026-09-29
Conventional vs Biologic Therapy in Pediatric IBDMesalamine—Not yet recruitingAssiut University2026-09-14
Bacillus Probiotic Spores in Supporting the Treatment of Chronic Inflammatory Bowel DiseaseMesalamineNot applicableRecruitingAnabio R&D2026-09-02
Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative ColitisMesalaminePhase 1 / Phase 2Enrolling by invitationAllama Iqbal Medical College2026-08-26
Comaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UCMesalaminePhase 4Not yet recruitingSir Run Run Shaw Hospital2026-08-24
ASAPP Study - Topical 5-ASA as Prophylaxis for Pouchitis in Ulcerative Colitis Patients After Pelvic Pouch SurgeryMesalaminePhase 4Not yet recruitingUniversity Hospital, Linkoeping2026-08-19
ND-12 Combined With H-6 for Adult Chronic Inflammatory DiarrheaMesalamineEarly phase 1RecruitingThe Second Hospital of Nanjing Medical University2026-08-17
New Triple Combination Therapy in Newly Diagnosed Type 2 DiabetesPioglitazonePhase 3Not yet recruitingSun Yat-sen University2026-06-09
AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative ColitisMesalamineNot applicableNot yet recruitingENBIOSIS BIOTECHNOLOGIES2026-06-02
Palmitoylethanolamide in Ulcerative ColitisMesalamineNot applicableRecruitingAin Shams University2026-05-27
Enhancing PCOS Management for Better Outcomes of Intracytoplasmic Sperm InjectionPioglitazoneNot applicableActive, not recruitingBeni-Suef University2026-05-22
Intraoperative Cognitive Load in Anesthesia Nurses Across Anesthetic PhasesPioglitazone—RecruitingHospital Clinic of Barcelona2026-05-05
Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation RatePioglitazonePhase 4RecruitingPAEC General Hospital, Islamabad2026-03-10
Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA TherapySaroglitazarPhase 3RecruitingZydus Therapeutics Inc.2026-02-20
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.PioglitazoneNot applicableRecruitingInstitute of Liver and Biliary Sciences, India2026-02-05
The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLDPioglitazonePhase 4Not yet recruitingThe Fourth Affiliated Hospital of Zhejiang University School of Medicine2025-12-17
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesSaroglitazarPhase 3RecruitingZydus Therapeutics Inc.2025-10-14
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver DiseaseSaroglitazarPhase 1RecruitingZydus Therapeutics Inc.2025-02-13
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary CholangitisSaroglitazarPhase 3Active, not recruitingZydus Therapeutics Inc.2024-05-23
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral AdrenoleukodystrophyLeriglitazonePhase 3Active, not recruitingMinoryx Therapeutics, S.L.2023-04-19
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyRosiglitazone—Active, not recruitingBrigham and Women's Hospital2022-02-02
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver DiseaseSaroglitazarPhase 1RecruitingZydus Therapeutics Inc.2021-09-16
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor MalignanciesRosiglitazonePhase 2RecruitingDan Zandberg2019-10-03

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Type 2 diabetes mellitus
0.86
PPARG-related familial partial lipodystrophy
0.82
Abnormality of the skeletal system
0.58
Obesity disorder
0.57
Coronary artery disorder
0.57
Colon carcinoma
0.52
Inherited obesity
0.51
Inherited lipid metabolism disorder
0.51
Proctitis
0.50

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
PPARG

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL235, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P37231, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.